Effect of probiotic in the treatment of pregnant women

Effects of probiotic supplementation on inflammatory factors and biomarkers of oxidative stress in

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201503035623N38

Enrollment

Registered

2015-03-10

Start date

2015-03-02

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy. Normal pregnancy

Interventions

Intervention 1: Intervention group: Probiotic capsule containing three strains of Lactobacillus acidophilus (2×109 CFU/g), Lactobacillus casei(2×109 CFU/g) and Bifidobacterium bifidum (2×109 CFU/g), d

Eligibility

Sex/Gender

Female

Age

18 Years to 37 Years

Inclusion criteria

Inclusion criteria: Pregnant women aged 18-37 years

Exclusion criteria

Exclusion criteria: Pregnant women with a recognized cause of recurrent miscarriages or a structural uterine abnormality History of rheumatoid arthritis, thyroid and parathyroid Adrenal diseases Hepatic or renal failure.

Design outcomes

Primary

Measure	Time frame
Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.	—

Secondary

Measure	Time frame
Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;VLDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;LDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Total Antioxidant Capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;VLDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;LDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Total Antioxidant Capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026